MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Molecular Interventions 8:281-283, (2008)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.8.6.5
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simmons, M. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Simmons, M. A.

Viewpoint

Let’s Go Rafting: Ligand Functional Selectivity May Depend on Membrane Structure

Mark A. Simmons

Department of Integrative Medical Sciences, NEOUCOM, Rootstown, OH 44272-0095

SUMMARY

Ligand functional selectivity occurs when full agonists at a single type of G protein–coupled receptor differ in their abilities to activate intracellular signaling pathways. Membrane rafts are cholesterol and sphingolipid-enriched areas of the cell membrane that tether signal protein complexes. Recent data suggests that functional selectivity of signaling through the µ opiate receptor depends on location of receptor and G proteins in raft or nonraft membrane domains. Changes in the distribution of signaling molecules in different membrane domains with age, disease, or drug history may contribute to variations in signaling and drug effects. Other results suggest that functional selectivity may account for therapeutic advantages of certain beta blockers used to treat heart failure. Functional selectivity could be exploited to develop drugs with more therapeutic value and fewer side effects.




This article has been cited by other articles:


Home page
Mol. Interv.Home page
A. Russo, U. J. K. Soh, and J. Trejo
Proteases Display Biased Agonism at Protease-Activated Receptors: Location matters!
Mol. Interv., April 1, 2009; 9(2): 87 - 96.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
R. M. van Rijn and J. L. Whistler
The Only Way Is Up: Preventing Opioid Tolerance by Promoting Cell Surface Expression of MOR-DOR Heterodimers?
Mol. Interv., December 1, 2008; 8(6): 277 - 280.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.